Analysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson’s Disease

by palligoelme@gmail.com | Feb 23, 2026 | Clinical Trials

​ Conditions: Essential Tremor, Movement Disorders; Essential Tremor; Essential Tremor-plus Sponsors: CND Life Sciences; National Institute of Neurological Disorders and Stroke (NINDS) Recruiting Conditions: Essential Tremor, Movement Disorders; Essential Tremor;...

Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)

by palligoelme@gmail.com | Feb 23, 2026 | Clinical Trials

​ Conditions: Hereditary Angioedema (HAE); Hereditary Angioedema – Type 1; Hereditary Angioedema – Type 2; HAE Interventions: Drug: ADX-324 Dose Level 1; Drug: ADX-324 Dose Level 2 Sponsors: ADARx Pharmaceuticals, Inc. Not yet recruiting Conditions:...

Resilience-Building for Advance Care Planning

by palligoelme@gmail.com | Feb 23, 2026 | Clinical Trials

​ Conditions: Advanced Cancer; End of Life Interventions: Behavioral: ROCKS; Behavioral: Usual Care Sponsors: University of Illinois at Chicago; National Institute of Nursing Research (NINR) Not yet recruiting Conditions: Advanced Cancer; End of Life Interventions:...

Detecting Type 2 Diabetes From Voice

by palligoelme@gmail.com | Feb 23, 2026 | Clinical Trials

​ Conditions: Type 2 Diabetes; Diabetes (DM); T2DM; T2DM (Type 2 Diabetes Mellitus) Sponsors: Thymia Limited Enrolling by invitation Conditions: Type 2 Diabetes; Diabetes (DM); T2DM; T2DM (Type 2 Diabetes Mellitus) Sponsors: Thymia Limited Enrolling by...

Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose

by palligoelme@gmail.com | Feb 20, 2026 | Clinical Trials

​ Conditions: Healthy Participants; Pharmacokinetics Interventions: Drug: Evolocumab Drug Substance A; Drug: Evolocumab Drug Substance B Sponsors: Amgen Recruiting Conditions: Healthy Participants; Pharmacokinetics Interventions: Drug: Evolocumab Drug Substance A;...

A Phase I First-in-human Trial of Bvax (B-cell Vaccination) in Addition to Standard of Care Chemoradiotherapy for Newly Diagnosed Glioblastoma

by palligoelme@gmail.com | Feb 20, 2026 | Clinical Trials

​ Conditions: Glioblastoma Interventions: Biological: B-cell vaccination Sponsors: Catalina Lee Chang Not yet recruiting Conditions: Glioblastoma Interventions: Biological: B-cell vaccination Sponsors: Catalina Lee Chang Not yet...